Navigation Links
Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
Date:5/29/2012

SEATTLE, May 29, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) will host an investor and analyst meeting to discuss unmet medical needs and targeted agents in myelofibrosis and high-risk myelodysplastic syndrome/acute myeloid leukemia, including data from pacritinib, the product candidate that CTI has agreed to acquire, and CTI's product candidate tosedostat. The event will take place on Sunday, June 3, 2012 in Chicago, Illinois.  The American Society of Clinical Oncology Annual Meeting is being held in Chicago from June 1-5, 2012.

Speakers at the event will include: Srdan Verstovsek, M.D., Ph.D., MD Anderson Cancer Center, Houston, Texas; Elihu Estey, M.D., Seattle Cancer Care Alliance, Seattle, Wash., Rami Komrokji, M.D., Moffitt Cancer Center, Tampa, Fla.; and David Steensma, M.D., F.A.C.P., Dana-Farber Cancer Institute, Boston, Mass.

The presentations will begin at 7 a.m. CDT /8 a.m. EDT /5 a.m. PDT /2 p.m. CET and conclude at approximately 8 a.m. CDT /9 a.m. EDT /6 a.m. PDT /3 p.m. CET. The presentations will be webcast live with slides and archived at www.celltherapeutics.com.

About Pacritinib

Pacritinib is an oral, once a day, tyrosine kinase inhibitor (TKI) with dual activity against JAK2 and FMS-like tyrosine kinase 3 (FLT3). Mutations in these kinases have been shown to be directly related to the development of a variety of blood related cancers including MPD, leukemia and lymphoma. Pacritinib has demonstrated encouraging results in phase 1 and 2 studies for patients with myelofibrosis and a phase 3 study is planned in this disease.

FLT3 is a commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome suggesting a possible future role for treatment of AML.

About Tosedostat

Tosedostat is an ora
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
2. Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
5. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
6. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
7. Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
8. Nile Therapeutics Reports 2012 First Quarter Financial Results
9. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio
10. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
11. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical ... Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it ... to address a potential issue with a clip ... the Axilla application of the SAM Junctional Tourniquet ...
(Date:8/29/2014)... Aug. 29, 2014  A Boston Scientific Corporation ... on stent removability and preliminary long term stricture ... in the August issue of the peer-reviewed journal, ... is being conducted in 11 countries and ... self-expanding metal stents (FCSEMS) after extended indwell (i.e., ...
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2
... 18, 2011 The National Association of Chain ... Association (NCPA) have sent a joint letter ... explaining the importance of pharmacies in Medicaid, offering ... to cut costs without endangering Medicaid beneficiaries, access ...
... Cornerstone Therapeutics Inc. (Nasdaq: CRTX ) today ... AM ET on Thursday, March 3, 2011, to discuss its ... 31, 2010. Financial results are expected to be released on ... financial markets. To participate in the live conference ...
Cached Medicine Technology:NACDS, NCPA Provide Insights to Governors and State Medicaid Directors Confronting Medicaid Budgetary Challenges 2NACDS, NCPA Provide Insights to Governors and State Medicaid Directors Confronting Medicaid Budgetary Challenges 3Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call 2Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call 3
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... introduced low cost SEO service for small businesses. , ... or start-ups cannot afford costly search engine optimization service. ... budget of small businesses into account. , On ... said, “We have introduced this low cost SEO service ...
(Date:8/30/2014)... 2014 The establishment and creation ... been one of the main strategies of the ... positive impact around the world. , Architecturally stellar ... trained executives and trainers deliver L. Ron Hubbard's ... Vital statistics demonstrate that significant reduction in crime, ...
(Date:8/30/2014)... Acne is a common problem millions of American cope ... than a daily nuisance, for some, it can have a crippling ... even lead to dramatic mood swings and depression. , Those ... up their skin. In some cases, that can make the problem ... error, those on a quest for clearer skin can now view ...
(Date:8/30/2014)... VA (PRWEB) August 30, 2014 Seniors Guide, ... articles recently that focus on Alzheimer’s Disease, Dementia, and ... revealed to the public of being diagnosed with the Alzheimer’s, ... latest movie, “I’ll Be Me”. The movie, out on ... while focusing on his diagnosis of the disease – which ...
(Date:8/30/2014)... Manhattan Beach, Calif. (PRWEB) August 30, 2014 ... Carol Francis helps listeners understand how they unknowingly developed insomnia ... and have restful nights during. Tune in to the ... . The show airs live on August 30, and ... For more information on programming, go to DrCarolFrancisTalkRadio.com. ...
Breaking Medicine News(10 mins):Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2
... , WEDNESDAY, Sept. 9 (HealthDay News) -- Young athletes ... cardiac death triggered by vigorous exercise, new Dutch research ... of death in young athletes, but no one knows ... reporting does not exist, the study authors noted. , ...
... Sept. 9 Reducing the risk of counterfeit drugs and contaminated medications ... the pharmaceutical and life sciences industries today, according to a new ... More than 50 percent of executives polled say their companies fail to ... their supply chain. , , (Logo: ...
... , LEWISTON, Maine and THOUSAND OAKS, Calif., Sept. 9 ... Challenge: A Journey for Hope, a cycling and 5K fundraising event scheduled ... Center for Cancer Hope & Healing at Central Maine Medical Center. ... Amgen,s Breakaway from Cancer ((R)) initiative, which aims to ...
... , FRANKLIN, Mass., Sept. 9 ... management company developing the needle-free Symphony(TM) tCGM System as ... and the Prelude(TM) SkinPrep System for transdermal drug delivery, ... at the Rodman & Renshaw 2009 Annual Global Investment ...
... , , , PORTLAND, Ore., Sept. ... chief executive officer of Regence BlueCross BlueShield: , , ... a pivotal conversation about health care reform. I applaud our nation,s ... "This August we saw an unfortunate polarization of our country. ...
... Calling all walkers, joggers, bikers and avid health & exercise buffs. Calling all couch potatoes, procrastinators, perpetual dieters and failed boot camp recruits! ... ... Thursday, September 10th, ... University Mall, ...
Cached Medicine News:Health News:Testing Young Athletes for Heart Defects May Save Lives 2Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 2Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 3Health News:IBM Study Reveals Drug Companies Struggle to Improve Supply Chain to Battle Counterfeiting, Safety Concerns and Global Complexity 4Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 2Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 3Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 4Health News:Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference 2Health News:Health Insurer Regence Continues to Advocate for Meaningful Health Reform 2Health News:Grand Opening: An Exercise Program for People Who Just Love To Dance 2
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Primary knee system, symmetrical in design....
Cruciate retaining, posterior stabilized and constrained components....
Maximum contact. Minimum wear. Outstanding results....
Medicine Products: